Trial Profile
Second of two planned phase III trials of eprotirome for the treatment of heterozygous familial hypercholesterolaemia
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 15 Feb 2012
Price :
$35
*
At a glance
- Drugs Eprotirome (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Sponsors Karo Bio
- 14 Feb 2012 Status changed from planning to discontinued, according to a Karo Bio media release.
- 07 Oct 2011 Not official study title
- 27 Aug 2010 New trial record